Rilmenidine

Rilmenidine

Clinical data
Routes of administration	Oral
ATC code	C02AC06 (WHO)
Pharmacokinetic data
Protein binding	7%
Metabolism	Minimal
Elimination half-life	8 hours
Excretion	Renal, unchanged
Identifiers
IUPAC name N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
CAS Number	54187-04-1
PubChem CID	68712
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H16N2O
Molar mass	180.247 g/mol

WikiDoc Resources for Rilmenidine
Articles
Most recent articles on Rilmenidine Most cited articles on Rilmenidine Review articles on Rilmenidine Articles on Rilmenidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Rilmenidine Images of Rilmenidine Photos of Rilmenidine Podcasts & MP3s on Rilmenidine Videos on Rilmenidine
Evidence Based Medicine
Cochrane Collaboration on Rilmenidine Bandolier on Rilmenidine TRIP on Rilmenidine
Clinical Trials
Ongoing Trials on Rilmenidine at Clinical Trials.gov Trial results on Rilmenidine Clinical Trials on Rilmenidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Rilmenidine NICE Guidance on Rilmenidine NHS PRODIGY Guidance FDA on Rilmenidine CDC on Rilmenidine
Books
Books on Rilmenidine
News
Rilmenidine in the news Be alerted to news on Rilmenidine News trends on Rilmenidine
Commentary
Blogs on Rilmenidine
Definitions
Definitions of Rilmenidine
Patient Resources / Community
Patient resources on Rilmenidine Discussion groups on Rilmenidine Patient Handouts on Rilmenidine Directions to Hospitals Treating Rilmenidine Risk calculators and risk factors for Rilmenidine
Healthcare Provider Resources
Symptoms of Rilmenidine Causes & Risk Factors for Rilmenidine Diagnostic studies for Rilmenidine Treatment of Rilmenidine
Continuing Medical Education (CME)
CME Programs on Rilmenidine
International
Rilmenidine en Espanol Rilmenidine en Francais
Business
Rilmenidine in the Marketplace Patents on Rilmenidine
Experimental / Informatics
List of terms related to Rilmenidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Rilmenidine is a prescription medication administered to treat hypertension. It is marketed under the brand name HYPERIUM®.

Form and Composition

Each tablet contains 1.544 mg rilmenidine dihydrogen phosphate, an amount equivalent to 1 mg rilmenidine base.

Properties

Hyperium, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Hyperium shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists.

Indications

Hypertension.

Contraindications

Severe depression, severe renal failure (creatinine clearance <15 ml/min), as a precaution in the absence of currently available studies.

Warning

Therapy should never be interrupted suddenly; the dosage should be reduced gradually.

Precautions

• As with all antihypertensive agents, regular medical monitoring is required when Hyperium is administered to patients with a recent history of cardiovascular disease (stroke, myocardial infarction).
• Alcohol consumption should be avoided during treatment.
• In patients with renal failure, no dosage adjustment is necessary if creatinine clearance is greater than 15 mL/min.
• In the absence of documented experiments in this area, Hyperium is not recommended for prescription to children.
• Pregnancy: as with all new molecules, administration of Hyperium should be avoided in pregnant women, although no teratogenic or embryotoxic effects have been observed in animal studies.
• Lactation: Hyperium is excreted in breast milk, and its use is therefore not recommended during lactation.
• Effects on the ability to drive motor vehicles or operate machinery: double-blind, placebo-controlled studies have not shown Hyperium to have any effect on alertness at therapeutic doses (1or 2 daily administrations of 1 mg). If these doses are exceeded, or if Hyperium is combined with other drugs capable of reducing alertness, vehicle drivers or machine operators should be warned of the possibility of drowsiness.

Drug interactions

Combinations not recommended: combination with MAOIs is not recommended; combination with tricyclic antidepressants requires prudence, as the antihypertensive activity of Hyperium may be partly antagonized.

Side Effects

• At a dose of 1 mg given as a single daily administration during controlled trials, the incidence of side effects was comparable to that observed with placebo.
• At a dose of 2 mg per day of Hyperium, controlled comparative studies versus clonidine (0.15 to 0.30 mg/day) or alpha2-methyldopa (500 to 1000 mg/day) demonstrated that the incidence of side effects was significantly lower with Hyperium than with either clonidine or a-methyldopa.

Side-effects are rare, non-severe, and transient at therapeutic doses: asthenia, palpitations, insomnia, drowsiness, fatigue on exercise, epigastric pain, dryness of the mouth, diarrhea, skin rash; and exceptionally, cold extremities, postural hypotension, sexual disorders, anxiety, depression, pruritus, edema, cramps, nausea, constipation, hot flushes.

Dosage and Route of Administration

The recommended dosage is 1 tablet per day as a single morning administration. If results are not adequate after 1 month of treatment, the dosage may be increased to 2 tablets per day, given in divided doses (1 tablet morning and evening) before meals. As a result of its good clinical and biological acceptability, Hyperium may be administered to both elderly and diabetic hypertensive patients. In patients with renal failure, no dosage adjustment is necessary in principle when the creatinine clearance is greater than 15 mL/min.

Treatment may be continued indefinitely.

Overdosage

No cases of massive absorption have been reported. Likely symptoms in such an eventuality would be marked hypotension and lowered alertness. In addition to gastric lavage, sympathomimetic agents may also required. Hyperium is only slightly dialysable.